144 related articles for article (PubMed ID: 38899172)
21. Rituximab treatment for adult patients with focal segmental glomerulosclerosis.
Ochi A; Takei T; Nakayama K; Iwasaki C; Kamei D; Tsuruta Y; Shimizu A; Shiohira S; Moriyama T; Itabashi M; Mochizuki T; Uchida K; Tsuchiya K; Hattori M; Nitta K
Intern Med; 2012; 51(7):759-62. PubMed ID: 22466834
[TBL] [Abstract][Full Text] [Related]
22. Circulating Anti-Rituximab Antibodies Do Not Affect Response to Rituximab in Steroid-Dependent Nephrotic Syndrome.
Angeletti A; Bruschi M; Colucci M; Kajana X; La Porta E; Caridi G; Lugani F; Ravani P; Vivarelli M; Cravedi P; Ghiggeri GM
Kidney Int Rep; 2022 Nov; 7(11):2509-2512. PubMed ID: 36531872
[No Abstract] [Full Text] [Related]
23. Effect of angiotensin converting enzyme gene I/D polymorphism in South Indian children with nephrotic syndrome.
Kumar Ramanathan AS; Karuppiah B; Vijayan M; Raju K; Mani D; Chinniah R; Thirunavukkarasu M; Malini Ravi P; Illiayaraja Krishnan J; Senguttuvan P
J Biomed Res; 2019 Jun; 33(3):201-207. PubMed ID: 30333281
[TBL] [Abstract][Full Text] [Related]
24. [Up to date of pathophysiology mechanism of idiopathic nephrotic syndromes: Minimal change disease and focal and segmental glomerulosclerosis].
Dumas De La Roque C; Combe C; Rigothier C
Nephrol Ther; 2018 Dec; 14(7):501-506. PubMed ID: 30150079
[TBL] [Abstract][Full Text] [Related]
25. A pilot study of anti-nephrin antibodies in podocytopaties among adults.
Chebotareva N; Vinogradov A; Birukova Y; Alentov I; Sergeeva N; Chemodanova D; Kononikhin AS; Moiseev SV
Nephrology (Carlton); 2024 Feb; 29(2):86-92. PubMed ID: 37864506
[TBL] [Abstract][Full Text] [Related]
26. A global antiB cell strategy combining obinutuzumab and daratumumab in severe pediatric nephrotic syndrome.
Dossier C; Prim B; Moreau C; Kwon T; Maisin A; Nathanson S; De Gennes C; Barsotti K; Bourrassi A; Hogan J; Deschênes G
Pediatr Nephrol; 2021 May; 36(5):1175-1182. PubMed ID: 33118048
[TBL] [Abstract][Full Text] [Related]
27. Electron microscopic findings suggestive of focal and segmental glomerulosclerosis in patients with steroid-resistant nephrotic syndrome.
Nili F; Saboori F; Jahanzad I; Mehrazma M
Ultrastruct Pathol; 2019; 43(1):6-12. PubMed ID: 30835594
[TBL] [Abstract][Full Text] [Related]
28. Successful Preemptive Kidney Transplantation With Rituximab Induction in a Patient With Focal Segmental Glomerulosclerosis and Massive Nephrotic Syndrome: A Case Report.
Kolonko A; Piecha G; Więcek A
Transplant Proc; 2016 Nov; 48(9):3092-3094. PubMed ID: 27932154
[TBL] [Abstract][Full Text] [Related]
29. [Nephrotic syndrome in childhood].
Reusz G; Szabó A; Fekete A
Orv Hetil; 2006 Nov; 147(47):2251-60. PubMed ID: 17380687
[TBL] [Abstract][Full Text] [Related]
30. Rituximab and chronic plasmapheresis therapy of nephrotic syndrome in renal transplantation patients with recurrent focal segmental glomerulosclerosis.
Rodríguez-Ferrero M; Ampuero J; Anaya F
Transplant Proc; 2009; 41(6):2406-8. PubMed ID: 19715934
[TBL] [Abstract][Full Text] [Related]
31. Relapse during and after regular single-dose rituximab treatment in adult patients with steroid-dependent nephrotic syndrome.
Saito E; Oura A; Kyo T; Ishigaki S; Kamei H; Nakamura Y; Soma J; Nakaya I
Clin Exp Nephrol; 2024 Jun; ():. PubMed ID: 38831157
[TBL] [Abstract][Full Text] [Related]
32. Rituximab therapy for focal segmental glomerulosclerosis and minimal change disease in adults: a systematic review and meta-analysis.
Hansrivijit P; Cheungpasitporn W; Thongprayoon C; Ghahramani N
BMC Nephrol; 2020 Apr; 21(1):134. PubMed ID: 32293308
[TBL] [Abstract][Full Text] [Related]
33. [No effect of rituximab in pediatric case of severe nephrotic syndrome and focal segmental glomeruloslerosis accompanied by renal insufficiency].
Hyla-Klekot L; Grenda R; Pulcer B
Pol Merkur Lekarski; 2008 Dec; 25(150):519-22. PubMed ID: 19205386
[TBL] [Abstract][Full Text] [Related]
34. Neph1 is reduced in primary focal segmental glomerulosclerosis, minimal change nephrotic syndrome, and corresponding experimental animal models of adriamycin-induced nephropathy and puromycin aminonucleoside nephrosis.
Hulkko J; Patrakka J; Lal M; Tryggvason K; Hultenby K; Wernerson A
Nephron Extra; 2014 Sep; 4(3):146-54. PubMed ID: 25404935
[TBL] [Abstract][Full Text] [Related]
35. Primary Focal Segmental Glomerulosclerosis Recurrence After Pediatric Renal Transplantation.
Baskın E; Avcı B; Gülleroğlu K; Akdur A; Moray G; Haberal M
Exp Clin Transplant; 2022 Mar; 20(Suppl 1):55-60. PubMed ID: 35384808
[TBL] [Abstract][Full Text] [Related]
36. A novel dosing approach for rituximab in glomerular diseases based on a population pharmacokinetic analysis.
Hartinger JM; Šíma M; Hrušková Z; Pilková A; Krátký V; Ryšavá R; Jančová E; Bobek D; Douša J; Francová I; Tesař V; Slanař O
Biomed Pharmacother; 2024 Jun; 175():116655. PubMed ID: 38678967
[TBL] [Abstract][Full Text] [Related]
37. Rituximab treatment for adults with refractory nephrotic syndrome: a single-center experience and review of the literature.
Kisner T; Burst V; Teschner S; Benzing T; Kurschat CE
Nephron Clin Pract; 2012; 120(2):c79-85. PubMed ID: 22286071
[TBL] [Abstract][Full Text] [Related]
38. Change of the course of steroid-dependent nephrotic syndrome after rituximab therapy.
Benz K; Dötsch J; Rascher W; Stachel D
Pediatr Nephrol; 2004 Jul; 19(7):794-7. PubMed ID: 15071769
[TBL] [Abstract][Full Text] [Related]
39. Rituximab for refractory cases of childhood nephrotic syndrome.
Kari JA; El-Morshedy SM; El-Desoky S; Alshaya HO; Rahim KA; Edrees BM
Pediatr Nephrol; 2011 May; 26(5):733-7. PubMed ID: 21279725
[TBL] [Abstract][Full Text] [Related]
40. Rituximab in The Management of Pediatric Steroid-Resistant Nephrotic Syndrome: A Systematic Review.
Jellouli M; Charfi R; Maalej B; Mahfoud A; Trabelsi S; Gargah T
J Pediatr; 2018 Jun; 197():191-197.e1. PubMed ID: 29680473
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
